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Background: Pain is a prevalent and distressing symptom in patients with cancer, having an enormous impact on
functioning and quality of life. Fragmentation of care, inadequate pain communication, and reluctance towards pain
medication contribute to difficulties in optimizing outcomes. Integration of patient self-management and professional
care by means of healthcare technology provides new opportunities in the outpatient setting.
Methods/Design: This study protocol outlines a two-armed multicenter randomized controlled trial that compares a
technology based multicomponent self-management support intervention with care as usual and includes an effect,
economic and process evaluation. Patients will be recruited consecutively via the outpatient oncology clinics and inpatient
oncology wards of one academic hospital and one regional hospital in the south of the Netherlands. Irrespective of the
stage of disease, patients are eligible when they are diagnosed with cancer and have uncontrolled moderate to severe
cancer (treatment) related pain defined as NRS≥ 4 for more than two weeks. Randomization (1:1) will assign patients to
either the intervention or control group; patients in the intervention group receive self-management support and
patients in the control group receive care as usual. The intervention will be delivered by registered nurses specialized
in pain and palliative care. Important components include monitoring of pain, adverse effects and medication as well
as graphical feedback, education, and nurse support. Effect measurements for both groups will be carried out with
questionnaires at baseline (T0), after 4 weeks (T1) and after 12 weeks (T2). Pain intensity and quality of life are the
primary outcomes. Secondary outcomes include self-efficacy, knowledge, anxiety, depression and pain medication
use. The final questionnaire contains also questions for the economic evaluation that includes both cost-effectiveness
and cost-utility analysis. Data for the process evaluation will be gathered continuously over the study period and
focus on recruitment, reach, dose delivered and dose received.
Discussion: The proposed study will provide insight into the effectiveness of the self-management support intervention
delivered by nurses to outpatients with uncontrolled cancer pain. Study findings will be used to empower patients and
health professionals to improve cancer pain control.
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Pain continues to be a prevalent and distressing symp-
tom described by patients during curative, palliative and
survivorship cancer care [1]. Each patient is unique and
the process of controlling cancer pain evolves differently
every time. At the inpatient or outpatient clinic, initial
pain assessments and medication prescriptions are pro-
vided in consultation with a health professional. Once at
home, patients and their caregivers face practical chal-
lenges and difficulties, because daily pain management
requires more than simply following medication pre-
scriptions [2]. Considering these challenges and difficul-
ties, together with the barriers that have been identified
in the outpatient setting [3–5], patients need to be sup-
ported in their cancer pain self-management [6].
Some arrangements are considered necessary for
effective self-management. Patients require assistance in
order to easily access information about pain and pain
medication, about what is normal and about when and
how to get help [7]. Patients also need to be able to
recognize and monitor pain and adverse effects in order
to get insight into their own situation and feedback
about how they are doing [8]. Patients will be motivated
when they are supported by their health professional to
have confidence and to undertake strategies to manage
better [9]. On that account, researchers point at multi-
component interventions that concentrate more inten-
sively on self-efficacy [10]. Patients require different
support in different situations when it comes to self-
management [11]. Patients themselves will select the
type of support needed in a given situation at a given
point in time [12]. Being embedded in routine clinical
practice, healthcare technology provides chances to inte-
grate these different arrangements and contribute to
patient self-management.
Providing patients with self-management support
requires health professionals to accept a slightly different
role and make a shift from clinical outcomes towards
providing help with day-to-day problems [13]. By virtue
of their expertise and focus on patients’ daily living,
nurses are able to make substantial contributions to pain
self-management [14]. Not being able to monitor pain
has been identified as an important barrier to adequate
pain management in the outpatient setting [15]. On-
going review and management of symptoms can be diffi-
cult to achieve for health professionals when outpatient
consultations take place occasionally whereas daily pain
fluctuations are very common. Healthcare technology is
promising in facilitating telemonitoring, enhancing symp-
tom management and improving quality of life [16].
We previously developed a technology based multi-
component self-management support intervention con-
sisting of an iPad application for patients that is connected
to a web application for nurses; both applications areembedded in routine clinical practice. Important compo-
nents include monitoring of pain, adverse effects and
medication as well as graphical feedback, education, and
nurse support. A small-scale evaluation confirmed feasi-
bility of the intervention in everyday life. Even though
patients and nurses had to get used to new tasks, respon-
sibilities and technology, they were positive about the
applications. Continuous monitoring in good and bad
moments underscored clinical relevance and use in prac-
tice. Adjustments were made to overcome technical
problems; suggestions for improvement gave input for
the set-up of the present large-scale evaluation.
Methods
Design
This study protocol outlines a two-armed multicenter ran-
domized controlled trial that compares a self-management
support intervention with care as usual and includes an ef-
fect, economic and process evaluation. The study protocol
was approved by the Medical Ethical Committee Atrium-
Orbis-Zuyd, the Netherlands (NL46552.096.13). Registration
of the study protocol was performed on December 29,
2014 (NCT02333968). A flowchart of the study design is
presented in Fig. 1.
Eligibility
Irrespective of the stage of disease, patients are eligible
when they are diagnosed with cancer and cope with
uncontrolled moderate to severe cancer (treatment)
related pain. Moderate to severe pain is defined as an
NRS score ≥4. Pain should be present for more than two
weeks and patients should live at home.
Patients will be excluded in case of an expected life
prognosis <3 months, chronic non-cancer (treatment)
related pain, known cognitive impairments, participation
in studies that interfere with this study, insufficient read-
ing skills and comprehension of the Dutch language, a
reduced vision and/or non-accessibility via telephone.
Recruitment
Patients will be recruited consecutively via the out-
patient oncology clinic and inpatient oncology wards of
one academic hospital and one regional hospital in the
south of the Netherlands. When patients are considered
eligible by the treating physician and are interested in
participation, they will receive a patient information
letter and an informed consent form. In the information
letter detailed information is given about the interven-
tion and study procedures. The fact that patients in the
intervention group receive an intervention alongside the
current care for their pain is emphasized. Patients will
be asked to read the information carefully and to discuss
participation with their partner, family or friends. The
contact details of the researcher are provided in the
Eligibility assessment of
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Fig. 1 Flowchart of the study design
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encouraged to contact the researcher or the independent
physician in case of questions or doubts. Two weeks will
be given to consider participation. Patients who decide
to participate in the study are asked to return their
informed consent. After informed consent, the treating
physician and the general practitioner will be informed
about the patient’s participation.
Randomization and blinding
Patients will be randomly allocated to the intervention
or control group with an allocation ratio of 1:1.
The randomization, stratified per center, is computer-
generated and will be carried out by an independent
research assistant; the allocation sequence is unknown
to the treating physicians and nurses who recruit pa-
tients and to the researcher who includes patients. After
informed consent, the independent research assistant
will reveal the group allocation to the researcher who in-
cludes the patient. Blinding of patients, nurses and treat-
ing physicians to group allocation is not possible due to
the nature of the intervention. Data will be analyzed
after encryption, without recognition of original vari-
ables including name, center and group allocation. An
independent research assistant will store the encryption
key and reveal the original variables at the end of the
study.
Intervention
Patients will receive the intervention alongside the pain
treatment that is provided to them by their treating
physician. The intervention will not interfere with, nor
be a substitute for, their usual pain treatment as the
treating physician remains responsible and decides on
follow-up. The intervention has been designed in a
co-creative process together with researchers, health
professionals, patients and technical experts. This process
resulted in an intervention that integrates patient self-
management and professional care by means of health-
care technology and consists of an iPad application for
patients and a web-application for nurses. Both applica-
tions are embedded in routine clinical practice.
Patient application
Patients register their pain, adverse effects, interference
of pain with activity or sleep, and satisfaction with treat-
ment by use of a pain diary twice-daily and optional
extra pain intensity scores within the iPad application.
Moreover, patients are requested to register intake of
“around-the-clock” (ATC) and “as needed” (PRN) medi-
cation in a personalized medication day schedule. Ac-
cordingly, registered pain intensity scores and medication
intake moments are depicted in a graph. Besides, patients
receive education about causes of pain, treatment of pain,recognition of symptoms that require action, and
methods that patients themselves can implement to
control pain. Patients are able to communicate with the
nurse via text message functionality within the applica-
tion in case of questions.
Nurse application
Based on the web application, the nurse monitors and
analyzes the patient’s situation once every workday,
taking into account completed pain diaries, scheduled
and actual medication intake and text messages. A
decision support system within the application, which
consists of an algorithm with questions, answers, and
colored risk flags supports nurses in their monitoring
tasks: red flags require immediate action, yellow flags
ask to keep an eye, and green flags indicate everything is
okay. In addition to sending text messages and consult-
ing patients by phone, nurses have the opportunity to
collaborate with the treating physician, pain specialist or
the multidisciplinary palliative team when pain relief is
inadequate.
In advance of the randomized controlled trial, nurses
took part in a 2-h instruction meeting about the nurse
application. These instructions are also summarized in
an instruction manual.
Procedure
For each patient in the intervention group an account
will be created in the nurse application, which will then
be linked to the patient application. Accordingly, a medi-
cation overview will be obtained from the pharmacist.
Pain medication from this overview will be entered into
the nurse application and activated to be visible in the
patient application. The nurse will process changes in
pain medication during the study period alike.
At baseline, a home visit will be scheduled. The nurse
carries out a pain anamnesis, checks pain medication
and provides patients with information about pain and
pain management. The researcher explains how to use
the patient application; information that is summarized
in an instruction manual as well. In case of technical
troubles with using the application during the study
period, patients will be advised to contact a helpdesk.
After twelve weeks the researcher will schedule another
home visit to conduct a semi-structured interview to ex-
plore experiences of the patient.
Care as usual
Outpatients with cancer pain enter the outpatient clinics
involved in the study basically via three different routes:
patients see their oncologist for follow-up and indicate
having pain; patients are referred by their general practi-
tioner with an increase in pain complaints; or patients
contact the oncology department themselves. Patients
Table 1 Outcome measures and time points of the effect
evaluation





Pain intensity BPI x x x
Cancer related quality of life EORTC-QLQ-C30 x x x
Secondary outcome measures
Self-efficacy CPSS-DLV x x x
Knowledge PKQ-DLV x x x
Anxiety and depression HADS x x x
Pain medication use Medication overview x x x
Additional measures
Socio-demographic data Questionnaire x
Medical data Medical record x
Co-interventions Questionnaire x
T0: Baseline - T1: 4 weeks - T2: 12 weeks
Hochstenbach et al. BMC Cancer  (2015) 15:416 Page 5 of 9are often treated by their oncologist with regard to
cancer pain. When the oncologist needs help, the pain
specialist is consulted. During an outpatient consultation
the pain specialist performs a pain anamnesis; checks
pain medication and changes prescriptions when needed.
Afterwards patients are seen again at the outpatient
clinic or contacted by phone for a follow-up consult-
ation. The timing and frequency of follow-up consulta-
tions differ and also depend on the type of medication
that has been prescribed; sometimes after four days,
sometimes after a week and when stabilized after two or
three weeks. When pain is adequately treated, the con-
sultation is closed. When pain gets worse and is difficult
to treat, the patient is admitted to the hospital. Patients
do often not receive information materials about pain
and pain treatment. Usually patients are neither asked to
monitor their pain scores, nor to register their medica-
tion intake on paper.
Co-interventions
For ethical and practical reasons, patients in both the
intervention and control group are not restricted in the
use of other methods to control pain. Because co-
interventions might bias results and conclusions though,
it is important to register these interventions and take
them into account in the analyses. Therefore, all patients
will be asked to report informational and practical
sources or tools that supported them in coping with or
controlling pain.
Data collection and outcome measures
Patients will be asked to complete postal questionnaires
at three time points; namely at baseline (T0), after four
weeks (T1), and after twelve weeks (T2). Measurements
are selected based on their psychometric properties
(validity, reliability), clinical utility and appropriateness
for the target setting and population. Patients in the
intervention group will be interviewed after the inter-
vention period as part of the process evaluation. A focus
group interview will be held with the nurses.
Effect evaluation
Primary outcome measures
Primary outcomes include pain intensity and quality of
life. Pain intensity will be measured with the Brief Pain
Inventory (BPI), an instrument frequently used to assess
pain in patients with cancer both within the clinical and
research setting [17, 18]. In addition to severity of pain
over the past three days, the 14-item BPI asks for loca-
tion of pain, pain medication and amount of pain relief
in the past 24-h, and impact of pain on daily function
over the past three days.
Quality of life will be measured with the EORTC Quality
of Life Questionnaire (EORTC-QLQ-C30 version 3). Thisinstrument is cancer specific, multi-dimensional and
appropriate for self-administration. Five functional scales,
three symptom scales, a global health and quality of life
scale as well as single items for other symptoms are cov-
ered. The EORTC-QLQ-C30 has shown acceptable levels
of reliability and validity [19]. Table 1 includes outcome
measures and time points for the effect evaluation.
Secondary outcome measures
Secondary outcomes include self-efficacy, knowledge,
anxiety, depression, and pain medication use. Self-
efficacy will be measured with the Chronic Pain Self-
efficacy Scale (CPSS-DLV) [20]. The Dutch language
version of the CPSS has two subscales (pain and symptom
management and physical functioning), each consisting of
10 items. Based on how secure they are to carry out a spe-
cific activity or to achieve a specific outcome, patients
score these items on a 10–100 scale (10 representing very
unsecure and 100 very secure). Reliability and validity have
been demonstrated for different pain conditions.
Ferrell’s Pain Knowledge Questionnaire (PKQ-DLV)
will be used to measure knowledge. The questionnaire
includes eight items that will be transformed to a 0–100
scale (0 is the lowest knowledge score; 100 is the highest
knowledge score). The PKQ-DLV has an acceptable reli-
ability and validity [21].
Anxiety and depression will be measured with the
Hospital Anxiety and Depression Scale (HADS). This self-
report scale consists of a depression and anxiety subscale,
each with 7 items. The HADS showed good performance to
assess symptom severity, anxiety disorders and depression
in somatic, psychiatric and primary care patients [22, 23].
Information about pain medication use will be derived
from the medication overview of the pharmacist.
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Relevant demographic and medical data will be collected
at the first measurement and retrieved from the medical
record. The final measurement will include a data sheet
that inventories co-intervention use during the study
period. These co-interventions include information
about pain and pain treatment, advices on how to con-
trol pain, pain medication schemes, reminders to take
medication, diaries to register pain scores or medication
intake, contact with the physician or nurse about pain or
other self-reported resources.
Process evaluation
Process evaluation components that will be assessed in-
clude recruitment, reach, dose delivered (completeness)
and dose received (exposure and satisfaction) [24]. The
intervention will be evaluated qualitatively by means of
semi-structured interviews with patients in the interven-
tion group directly after the intervention period and
with a focus group interview with nurses after the studyTable 2 Components, operationalization and methods of the proce
Component and definition Operationalization
Recruitment




• Reasons for non-
Reach
Proportion of the intended population that participated
in the intervention
• Characteristics of
• Number of patie
or dropped out
• Reasons for with
Dose delivered (completeness)
Extent to which the intervention is actually delivered
to patients and nurses
• Implementation
• Functioning of th
intended
Dose received (exposure)
Extent to which patients and nurses received and used
the intervention
• Opinion about th
and implement t
• Patients’ and nur
intervention
• Number of action
monitored data
Dose received (satisfaction)




• Overall opinion o
• Facilitators and b
• The interventionperiod. Quantitative data will be collected continuously
from plans, logbooks, log files and checklists. Compo-
nents, operationalization and methods of the process
evaluation are summarized in Table 2.
Economic evaluation
The economic evaluation will be performed from a societal
perspective, which implies that all relevant medical and
non-medical costs and effects are taken into account [25].
The economic evaluation will involve a combination of a
cost-effectiveness analysis (CEA) and a cost-utility analysis
(CUA). Compared to care as usual, the self-management
support intervention is expected to result in cost effective
care with improvements in pain intensity and quality
adjusted life years (QALYs).
The CEA includes intervention costs, healthcare costs,
patient and family costs, and costs outside the health
care sector. To limit the burden for patients, cost data
are preferably collected by means of retrospective ques-
tionnaires that should not exceed a recall time frame ofss evaluation
Data collection method
ed within and outside hospitals to • Recruitment plan
participation • Recruitment logbook
patients • Socio-demographic questionnaire
nts that completed the intervention • Server log file
drawal • Enrolment logbook
of the home visit as intended • Checklist
• Interviews patients
e patient and nurse application as • Interviews nurses
• Server log file
• Helpdesk logbook
e ability of patients to understand
he intervention
• Interviews patients
ses’ adherence towards the • Interviews nurses
s nurses applied in follow-up of • Server log file
efits, burden, and supportiveness of
by patients and nurses
• Interviews patients
• Interviews nurses
f patients and nurses
arriers in applying
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cluded in the final measurement, retrospectively asking
for costs made during the study period of three months.
Existing questionnaires are combined to identify all
relevant costs.
Within the CUA outcomes will be measured by means
of the EuroQol (EQ-5D-5L), a self-administered ques-
tionnaire that consists of a descriptive system and a
visual analogue scale [27].
Sample size and power calculation
The power calculation is estimated by a two-tailed ana-
lysis, based on the assumption that alpha and beta equal
0.05 and 0.2 respectively. The mean pain intensity is
expected to decrease 1.5 on a 0–10 point-scale in the
intervention group compared to the contol group. To
have adequate power to test the effect of the intervention
on pain intensity, the sample size will equal 62.8 in both
the intervention as well as control group. Taking into con-
sideration 15 % of non-response, a total of 73 patients per
group will be needed. In addition, during the study period
20 % of patients are expected to drop out because they are
too ill or died (loss to follow-up). Therefore, 87 patients
per group will be needed to have adequate power.
Planned analyses
Quantitative data will be analyzed using the Statistical
Package for the Social Sciences (SPSS) version 21. A
directed content analysis method will be followed to
analyze data qualitatively.
Analyses effect evaluation
Intention to treat analyses and per protocol analyses will
be conducted. Descriptive statistics and frequency distri-
butions will be generated for demographic, disease and
pain related characteristics. Independent student t-tests
and chi-square tests will be performed to determine
comparability in baseline characteristics between pa-
tients randomized to the intervention and control group.
To evaluate the effect of the intervention and changes
over time, an analysis for longitudinal data will be con-
ducted using repeated measures analysis of variance
(ANOVA) or mixed regression models. The number of
dropouts in this study, mainly by severe illness and
death, will probably result in an unbalanced dataset.
Mixed regression models offer an alternative for dealing
with unbalanced data sets. Therefore, changes over time
and differences between subgroups will be tested by
using the Random Intercept Model.
Analyses process evaluation
Quantitative data will be analyzed by means of descrip-
tive statistics. The information from semi-structured and
focus group interviews as well as the notes of the nurseswill be analyzed qualitatively. Data will be summarized,
coded and organized into categories. These categories
reflect the emerging themes for patients’ and health
professionals’ experiences with the intervention.
Analyses economic evaluation
Valuation of costs will be based on the Dutch manual for
cost analysis in health care research [28]. Differences in
costs and effects will be presented in an incremental cost-
effectiveness ratio (ICER) and an incremental cost-utility
ratio (ICUR). The ICER and ICUR represent the difference
in mean costs of the intervention and control group in the
numerator and the difference in mean effects of the inter-
vention and control group in the denominator.
Discussion
As actual cancer pain management is practiced particularly
at home and outpatients face difficulties in putting pre-
scriptions into practice [2], supporting self-management
appears to be a promising solution. Healthcare technology
provides opportunities to follow-up patients beyond the
walls of the outpatient clinic. The RCT involves the
evaluation of a technology based multicomponent self-
management support intervention that combines monitor-
ing of pain, adverse effects and medication with graphical
feedback, education, and nurse support. Compared to care
as usual, self-management support is expected to result in
better pain control and better quality of life.
The intervention is different from previous attempts in
its multicomponent and interactive approach. Complex
interventions having several interacting components
require good theoretical understanding and the use
of different outcome measures to evaluate underlying
mechanisms [29]. Quantitative and qualitative data col-
lection will be combined and different outcomes related
to cancer pain and self-management will be measured.
While clinical effectiveness is of primary concern, the in-
formation from the process and economic evaluation
will provide important in-depth insights into the success
of the intervention in order to better interpret results
and improve future implementation [30, 31].
Recruitment of oncological patients in any study can
be challenging. When the study involves symptom man-
agement, rather than disease treatment, recruitment
even asks for more efforts [32]. Health professionals pro-
tect their patients because of high disease and symptom
burden; patients most in need for these interventions
often feel too ill or overwhelmed. Provision of informa-
tion about the intervention and both advantages and dis-
advantages of study participation to health professionals
and patients is believed to increase enrollment [33].
Departments of participating centers will be visited regu-
larly and study information as well as number of
inclusion updates will be disseminated repeatedly via
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shortly after they received the informed consent docu-
ments from their treating physician, patients will be
called by the researcher in order to provide more infor-
mation about the study and to answer questions. These
contact moments with both health professionals as well
as patients will reveal important information as regards
the reasons for health professionals not to recruit and for
patients not to participate; information that will be used
in future contacts to increase enrollment. Others lessons
learned from previous research have been taken into
account in the preparation of this RCT: the content and
frequency of questionnaires have been minimized, flexi-
bility will be offered in scheduling home visits and a
helpdesk will be available for technological support and
assistance with filling out questionnaires [32–34].
Study outcomes will contribute to the understanding on
interventions improving cancer pain in outpatients by
means of self-management support. Evaluations will
also provide important information as to whether a mixed
population of cancer patients regarding age, socio-
economic status and complexity of disease and medica-
tion, is accepting healthcare technology. The intervention
could be base for other cancer related health problems or
for pain problems in other chronic diseased populations.
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